Medical School, Sigmund Freud University, 1020 Vienna, Austria.
Department of Internal Medicine V with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, 1130 Vienna, Austria.
Int J Mol Sci. 2020 Apr 24;21(8):3025. doi: 10.3390/ijms21083025.
Although the RAS-pathway has been implicated as an important driver in the pathogenesis of chronic myelomonocytic leukemia (CMML) a comprehensive study including molecular and functional analyses in patients with progression and transformation has not been performed. A close correlation between RASopathy gene mutations and spontaneous in vitro myeloid colony (CFU-GM) growth in CMML has been described. Molecular and/or functional analyses were performed in three cohorts of 337 CMML patients: in patients without (A, = 236) and with (B, = 61) progression/transformation during follow-up, and in patients already transformed at the time of sampling (C, = 40 + 26 who were before in B). The frequencies of RAS-pathway mutations (variant allele frequency ≥ 20%) in cohorts A, B, and C were 30%, 47%, and 71% ( < 0.0001), and of high colony growth (≥20/10 peripheral blood mononuclear cells) 31%, 44%, and 80% ( < 0.0001), respectively. Increases in allele burden of RAS-pathway mutations and in numbers of spontaneously formed CFU-GM before and after transformation could be shown in individual patients. Finally, the presence of mutations in RASopathy genes as well as the presence of high colony growth prior to transformation was significantly associated with an increased risk of acute myeloid leukemia (AML) development. Together, RAS-pathway mutations in CMML correlate with an augmented autonomous expansion of neoplastic precursor cells and indicate an increased risk of AML development which may be relevant for targeted treatment strategies.
虽然 RAS 通路已被认为是慢性骨髓单核细胞白血病 (CMML) 发病机制中的重要驱动因素,但尚未在进展和转化的患者中进行包括分子和功能分析的综合研究。已经描述了 RAS 病基因突变与 CMML 中自发性体外髓样集落(CFU-GM)生长之间的密切相关性。对三个队列的 337 名 CMML 患者进行了分子和/或功能分析:在随访期间没有(A,n=236)和有(B,n=61)进展/转化的患者中,以及在采样时已经转化的患者中(C,n=40+26 之前在 B 队列中)。在队列 A、B 和 C 中,RAS 通路突变(等位基因变异频率≥20%)的频率分别为 30%、47%和 71%(<0.0001),高集落生长(≥20/10 外周血单核细胞)的频率分别为 31%、44%和 80%(<0.0001)。可以在个体患者中显示出在转化前后 RAS 通路突变的等位基因负担增加和自发形成 CFU-GM 的数量增加。最后,RAS 病基因突变的存在以及在转化前存在高集落生长与急性髓细胞白血病(AML)发展的风险增加显著相关。总之,CMML 中的 RAS 通路突变与肿瘤前体细胞的自主扩张增加相关,并表明 AML 发展的风险增加,这可能与靶向治疗策略相关。